DE69935159D1 - Screening-verfahren - Google Patents

Screening-verfahren

Info

Publication number
DE69935159D1
DE69935159D1 DE69935159T DE69935159T DE69935159D1 DE 69935159 D1 DE69935159 D1 DE 69935159D1 DE 69935159 T DE69935159 T DE 69935159T DE 69935159 T DE69935159 T DE 69935159T DE 69935159 D1 DE69935159 D1 DE 69935159D1
Authority
DE
Germany
Prior art keywords
salt
slc
mch
screening
appetite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69935159T
Other languages
English (en)
Other versions
DE69935159T2 (de
Inventor
Masaaki Mori
Yukio Shimomura
Shiro Takekawa
Tsukasa Sugo
Yoshihiro Ishibashi
Chieko Kitada
Nobuhiro Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27314502&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69935159(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of DE69935159D1 publication Critical patent/DE69935159D1/de
Application granted granted Critical
Publication of DE69935159T2 publication Critical patent/DE69935159T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/808—Automated or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
DE69935159T 1998-12-28 1999-12-27 Screening-verfahren Expired - Lifetime DE69935159T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP37445498 1998-12-28
JP37445498 1998-12-28
JP12268899 1999-04-28
JP12268899 1999-04-28
JP24930099 1999-09-02
JP24930099 1999-09-02
PCT/JP1999/007336 WO2000040725A1 (en) 1998-12-28 1999-12-27 Screening method

Publications (2)

Publication Number Publication Date
DE69935159D1 true DE69935159D1 (de) 2007-03-29
DE69935159T2 DE69935159T2 (de) 2007-10-25

Family

ID=27314502

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69935159T Expired - Lifetime DE69935159T2 (de) 1998-12-28 1999-12-27 Screening-verfahren

Country Status (9)

Country Link
US (1) US6991908B1 (de)
EP (1) EP1143000B1 (de)
KR (1) KR20020008111A (de)
CN (1) CN1344321A (de)
AT (1) ATE354098T1 (de)
AU (1) AU1802000A (de)
CA (1) CA2356412A1 (de)
DE (1) DE69935159T2 (de)
WO (1) WO2000040725A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
WO2000070347A1 (en) * 1999-05-19 2000-11-23 Astrazeneca Ab Assays for agonists, agonists and inverse agonists of melanin concentrating hormone (mch) binding to the somatostatin-like receptor (slc-1)
WO2001005947A1 (en) 1999-07-14 2001-01-25 Merck & Co., Inc. Melanin-concentrating hormone receptor
US6930185B2 (en) * 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
JP4780365B2 (ja) * 2000-07-05 2011-09-28 武田薬品工業株式会社 Ｍｃｈ受容体アンタゴニスト・アゴニストのスクリーニング方法
DE60143525D1 (de) * 2000-07-05 2011-01-05 Takeda Pharmaceutical Verfahren zum screenen von mhc-rezeptorantagonisten oder -agonisten
US7078484B2 (en) 2001-04-19 2006-07-18 Neurogen Corporation Melanin concentrating hormone receptors
US7078187B2 (en) 2001-04-19 2006-07-18 Neurogen Corporation Melanin concentrating hormone receptors
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
CA2505372A1 (en) 2002-11-06 2004-05-27 Tularik Inc. Fused heterocyclic compounds
MXPA06001636A (es) 2003-08-13 2006-04-28 Amgen Inc Antagonista del receptor de la hormona concentradora de melanina.
WO2008001778A1 (fr) 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Animal génétiquement modifié et son utilisation
US12008266B2 (en) 2010-09-15 2024-06-11 Pure Storage, Inc. Efficient read by reconstruction
US11614893B2 (en) 2010-09-15 2023-03-28 Pure Storage, Inc. Optimizing storage device access based on latency
WO2016133374A1 (ko) * 2015-02-17 2016-08-25 싸이퍼롬, 인코퍼레이티드 자궁수축억제제 부작용 방지를 위한 개인별 단백질 손상 정보 기반의 자궁수축억제제 선택 방법
CN111443209B (zh) * 2020-03-26 2022-12-20 中国中医科学院医学实验中心 一种筛选非激动剂型PPARγ配体的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049655A (en) * 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
CA2120518C (en) * 1991-10-01 1998-10-13 Monika Konig A method of identifying ligands and antagonists of ligands
FR2687680A1 (fr) * 1992-02-20 1993-08-27 Centre Nat Rech Scient Procede de marquage de proteines et de peptides par acylation de leur fonction alpha aminee par un reactif comportant une fonction carboxylique activee.
JPH08193099A (ja) * 1994-11-14 1996-07-30 Takeda Chem Ind Ltd 新規ｇ蛋白質共役型レセプター蛋白質、その製造法および用途
AU4522796A (en) * 1994-12-16 1996-07-03 Smithkline Beecham Corporation Human somatostatin-like receptor
US5849708A (en) * 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
US20020038007A1 (en) * 1996-12-11 2002-03-28 Ames Robert S. Method of finding agonist and antagonist to human 11cb splice variant
EP0848060A3 (de) 1996-12-11 2000-02-02 Smithkline Beecham Corporation Humane 11CB Splice-Varianten
IL130880A (en) * 1997-04-14 2004-03-28 Arena Pharm Inc Method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
WO1998052554A1 (en) * 1997-05-23 1998-11-26 Bristol-Myers Squibb Company Spirocyclopropyl fluorenes as melatonergic agents
JP2001525178A (ja) * 1997-12-03 2001-12-11 スミスクライン ビーチャム コーポレーション ヒト１１ｃｂスプライス変異体に対するアゴニストおよびアンタゴニストの探索方法
US6221613B1 (en) * 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof

Also Published As

Publication number Publication date
EP1143000A1 (de) 2001-10-10
US6991908B1 (en) 2006-01-31
AU1802000A (en) 2000-07-24
ATE354098T1 (de) 2007-03-15
WO2000040725A1 (en) 2000-07-13
CA2356412A1 (en) 2000-07-13
KR20020008111A (ko) 2002-01-29
DE69935159T2 (de) 2007-10-25
EP1143000B1 (de) 2007-02-14
CN1344321A (zh) 2002-04-10
EP1143000A4 (de) 2005-01-12

Similar Documents

Publication Publication Date Title
DE69935159D1 (de) Screening-verfahren
FI974173A (fi) Endoteliiniantagonisteja ja endoteliinisyntaasi-inhibiittoreita kohdunsupistussairauksien, raskausmyrkytyksen esivaiheen, valtimon haurausk ovetustaudin ja verenpainetaudin ennaltaehkäisemiseksi ja hoitamiseksi sekä hormonipalautusterapiaan
NO984513D0 (no) Benzyl(iden)-laktam-derivater, deres fremstilling og deres anvendelse som selektive (ant)agonister for 5-HT1A- og 5-HT1D-reseptorer
ES2196063T3 (es) Utilizacion de agentes antagonistas competitivos de progesterona para la preparacion de medicamentos destinados al tratamiento de hemorragias uterinas disfuncionales.
ES500424A0 (es) Procedimiento de preparar agentes para la embolizacion qui- rurgica
BR9908269A (pt) Método e aparelho para proporcionar um ajuste de tempo para um sistema de comunicação sem fio
BR9304376A (pt) Coxim higiênico interlabial, e processo para fazer dispositivo de proteção higiênica
DE60035840D1 (de) Chirurgische Vorrichtung zum Anbringen von resorbierbaren Nieten / Stangen
FR2643251B1 (fr) Suture chirurgicale, notamment pour fermeture de sternotomie
HUP9903671A3 (en) Antagonists of gonadotropin releasing hormone, pharmaceutical compositions and process for producing them
FR2629998B1 (fr) Agrafe chirurgicale de suture cutanee et outil pour sa mise en oeuvre
IT7850944A0 (it) Perfezionamento negli imballi per suture oftalmiche
DE60005471D1 (de) EP4 Rezeptor selektive Agonisten zur Behandlung der Osteoporose
DE3860746D1 (de) Stationaere vorrichtung zur verkehrsueberwachung.
FR2559383B1 (fr) Dispositif de mise en forme pour tampon hygienique
NO20013556D0 (no) Selektiv hydrogeneringsprosess og katalysator for denne
IS2691B (is) Áætlun um lyfjaskammta og lyfjasamsetningar til getnaðarvarnar í neyð
DE69005353D1 (de) Vorrichtung zum Schneiden von Gipsverbänden.
BR9007098A (pt) Dispositivo contraceptivo intra-uterino
FR2746292B1 (fr) Agrafe chirurgicale, dispositif pour sa mise en oeuvre, et agrafeuse correspondante
FR2637858B1 (fr) Maitre-cylindre de freinage, methode de reglage du maitre-cylindre et dispositif pour la mise en oeuvre de la methode
EP1034002A4 (de) Verfahren zur inhibierung eines vorzeitigen reissens der fötalen membran, reifung der uteruscervix sowie vorbereitende arbeiten
DE69014971D1 (de) Verfahren und Vorrichtung zum Abtrennen der Beine von Schlachtgeflügel.
AU1285292A (en) Process and apparatus for extended, non-invasive monitoring of uterine contractions
UA32373A (uk) Спосіб реабілітації жінок, які перенесли атонічні маткові кровотечі з акушерською гістеректомією

Legal Events

Date Code Title Description
8363 Opposition against the patent
R082 Change of representative

Ref document number: 1143000

Country of ref document: EP

Representative=s name: WEISS, WOLFGANG, DIPL.-CHEM.UNIV. DR.RER.NAT., DE